PKM2 Inhibitor (Compound 3k): Selective Pyruvate Kinase M2 Blockade for Cancer Metabolism Research

Executive Summary: PKM2 inhibitor (compound 3k) is a highly selective molecular tool that targets the pyruvate kinase M2 (PKM2) isoform, which is upregulated in many tumors and drives aerobic glycolysis (Warburg effect) [APExBIO product page]. The agent exhibits an in vitro IC₅₀ of 2.95 μM for PKM2 and demonstrates nanomolar-range antiproliferative effects in high-PKM2 cancer cell lines while sparing normal cells. In vivo efficacy has been established in SK-OV-3 ovarian cancer xenografts, where oral dosing at 5 mg/kg every 48 hours for 31 days significantly reduced tumor burden with no major toxicity. The compound's mechanism involves disruption of glycolytic flux and potential modulation of immunometabolic pathways, as validated in both cancer and inflammatory disease models (Wu et al., 2025). PKM2 inhibitor (compound 3k) is supplied by APExBIO (SKU: B8217) and offers robust performance in cell-based and animal studies for researchers investigating tumor cell-specific PKM2 targeting and glycolytic pathway inhibition.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a glycolytic enzyme pivotal to the metabolic reprogramming of cancer cells. Tumors often upregulate PKM2 to facilitate high rates of aerobic glycolysis, supporting rapid proliferation and survival under hypoxic conditions (Wu et al., 2025). PKM2 mediates the final step of glycolysis, converting phosphoenolpyruvate to pyruvate and generating ATP. Unlike its PKM1 isoform, PKM2 can exist in inactive dimeric forms that promote glycolytic intermediates' shunting into biosynthetic pathways, further supporting oncogenesis. Inhibition of PKM2 selectively impairs tumor cell metabolism while sparing normal cells that predominantly express PKM1 or other isoforms. This selectivity makes PKM2 an attractive target for cancer metabolism therapy, as well as for modulating immune cell polarization in diseases such as severe acute pancreatitis (Wu et al., 2025).

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) directly binds to the PKM2 isoform and inhibits its catalytic activity, with an IC₅₀ of 2.95 μM measured under standard in vitro enzyme assay conditions (APExBIO). This blockade prevents conversion of phosphoenolpyruvate to pyruvate, disrupting ATP production and the supply of glycolytic intermediates required for biosynthesis in rapidly dividing cells. Selectivity is achieved through preferential inhibition of PKM2 over other pyruvate kinase isoforms, as determined by enzyme kinetic studies. In cancer cells, this results in impaired proliferation and induction of cell death pathways, including autophagic cell death, due to energy stress. In macrophages, PKM2 inhibition can also shift polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes, as shown in inflammatory disease models (Wu et al., 2025).

Evidence & Benchmarks

• PKM2 inhibitor (compound 3k) exhibits an IC₅₀ of 2.95 μM against purified PKM2 enzyme in vitro (APExBIO).
• Demonstrates antiproliferative activity in HCT116, Hela, and H1299 cancer cell lines with IC₅₀ values of 0.18, 0.29, and 1.56 μM respectively, under standard cell viability assay conditions (APExBIO).
• Shows higher cytotoxicity toward tumor cells compared to normal BEAS-2B cells in dose-response studies (APExBIO).
• Oral administration at 5 mg/kg every 2 days for 31 days significantly reduces tumor volume and weight in BALB/c nude mice bearing SK-OV-3 ovarian xenografts, with no major organ toxicity or significant weight loss (APExBIO).
• In models of severe acute pancreatitis, a PKM2 inhibitor (3k) partially reverses the protective effects of USP7 knockdown, confirming that USP7's immunomodulatory actions depend on PKM2-mediated metabolic reprogramming (Wu et al., 2025).

This article extends the analysis in "PKM2 Inhibitor (Compound 3k): Redefining Tumor Metabolism" by focusing on up-to-date in vivo and immunometabolic evidence, and clarifies workflows discussed in "Optimizing Cell-Based Assays with PKM2 Inhibitor (Compound 3k)" by providing quantitative efficacy and selectivity data.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is indicated for research in cancer cell metabolism inhibition, tumor-specific glycolytic pathway disruption, and immunometabolic modulation. It is suitable for in vitro cell viability, proliferation, and cytotoxicity assays, as well as for in vivo antitumor efficacy studies. The compound is particularly relevant for ovarian cancer research and for disease models where PKM2 is implicated in immunometabolic reprogramming.

Common Pitfalls or Misconceptions

• PKM2 inhibitor (compound 3k) is not active against PKM1 or non-glycolytic metabolic pathways at tested concentrations; it should not be used for non-PKM2-dependent tumors.
• The compound is insoluble in ethanol and water; improper solvent use may lead to assay failure.
• Long-term storage of stock solutions is not recommended due to potential degradation; prepare fresh solutions as needed.
• The agent is a research tool and not approved for clinical therapeutic use in humans.
• Effects on immune cells are context-dependent and may not generalize across all inflammatory models.

Workflow Integration & Parameters

For cell-based assays, dissolve PKM2 inhibitor (compound 3k) at ≥34.5 mg/mL in DMSO with gentle warming. Use freshly prepared stock solutions and avoid repeated freeze-thaw cycles. Recommended in vitro working concentrations range from 0.1 to 10 μM, depending on cell line PKM2 expression. For animal studies, administer orally at 5 mg/kg every 48 hours for up to 31 days; monitor animal weight and organ function. Store solid compound at -20°C. For detailed assay compatibility and troubleshooting, see scenario-driven guidance in "Scenario-Driven Best Practices with PKM2 Inhibitor (Compound 3k)", which this article updates with new in vivo data and PKM2-selectivity benchmarks.

Conclusion & Outlook

PKM2 inhibitor (compound 3k) provides a robust, selective approach for dissecting cancer cell metabolism and immunometabolic regulation. Its nanomolar efficacy in tumor models and favorable selectivity profile make it a valuable tool for preclinical research. Further studies are warranted to map its utility across cancer types and immune cell contexts. For comprehensive product details and ordering, refer to the PKM2 inhibitor (compound 3k) page at APExBIO.